AlphaCore Pharma

AlphaCore Reports Positive Phase 1 Results For New Heart DrugAlphaCore Pharma announced Tuesday that results from the company’s Phase 1 clinical trial have met the primary endpoint by demonstrating the safety and tolerability of the drug ACP-501 (recombinant human LCAT).
AlphaCore Pharma Starts Clinical Trial Of New Heart DrugThe biopharmaceutical company AlphaCore Pharma Friday announced it had started a Phase 1 study of its drug candidate, ACP-501, for the treatment of high-risk atherosclerosis and serious lipid metabolism disorders.
Ann Arbor Firm Part Of Cholesterol Treatment GrantAnn Arbor-based AlphaCore Pharma and Rockville, Md.-based Advanced Bioscience Laboratories Tuesday announced funding from the National Heart, Lung and Blood Institute, part of the National Institutes of Health, to manufacture a new treatment for a type of coronary artery disease that runs in families.
Best Winter Festivals In Metro Detroit
Thanksgiving Parade Guide

Watch & Listen